"Q1 2026 revenue came in at $19.80 billion, up 55.5% year over year, with non-GAAP EPS of $8.55 against a $6.79 consensus. Companies this size do not grow this fast by accident."
"The quarterly payout climbed from $1.30 in 2024 to $1.50 across 2025 and then $1.73 in Q1 2026. Annual dividends went from $2.08 in 2017 to $6 in 2025."
"Foundayo, the only approved GLP-1 pill with no food or water restrictions, opens an oral market Ricks pegs at 'over 1 billion people around the world with obesity and related conditions.'"
"On February 9, 2026, CEO Ricks bought 38,913 shares at $1,044.67, alongside more than a dozen other executives. Four directors have kept buying in February, March, and April."
Eli Lilly is experiencing significant growth, particularly in the GLP-1 market for diabetes and obesity. The Q1 2026 revenue reached $19.80 billion, a 55.5% increase year over year. Mounjaro and Zepbound contributed significantly to this growth. The company has also increased its dividend payouts consistently, indicating strong financial health. The pipeline includes Foundayo, which targets a large market, and insider buying from executives further supports confidence in the company's future prospects.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]